Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1M | 0 | 0 | 0 | 0 |
| Operating Income | -81M | -144M | -126M | -84M | -42M |
| EBITDA | -80M | -142M | -125M | -83M | -41M |
| Net Income | -62M | -138M | -117M | -82M | -42M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.32
+7.32% today
1Y Change
-33.70%
Window
Jun 27, 2025 → Jun 17, 2026
Coverage: 244 bars · Jun 27, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Biomea Fusion, Inc. (BMEA) is a Healthcare stock with a market cap of $90.00M. The stock last traded around $1.32 and down 33.7% across the available one-year price window (Jun 27, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +69.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +69.2%, free cash flow +41.5% with operating margin 0.0% and ROIC -170.7%. Stock Foundry combines BMEA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
BMEA
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
BMEA Max Drawdown
-64.16%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BMEA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$41.6M
+49.2% YoY
Free Cash Flow
-$38.6M
+39.1% YoY
Revenue Growth
+0.0%
EPS Growth
+69.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1M | 0 | 0 | 0 | 0 |
| Operating Income | -81M | -144M | -126M | -84M | -42M |
| EBITDA | -80M | -142M | -125M | -83M | -41M |
| Net Income | -62M | -138M | -117M | -82M | -42M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 56M | 58M | 177M | 112M | 146M |
| Total Assets | 59M | 80M | 200M | 129M | 186M |
| Total Liabilities | 29M | 28M | 31M | 21M | 7M |
| Shareholder Equity | 30M | 52M | 169M | 109M | 179M |
| Total Debt | 2M | 9M | 10M | 2M | 3M |
| Net Debt | -54M | -50M | -167M | -110M | -143M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
35M
+43.2% YoY
Capital Expenditures
3M
-207.9% YoY
Free Cash Flow
39M
+39.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-243.7%
Debt / Equity
0.05x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.